The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

By A. Kharitonenkov, V. Wroblewski, A. Koester, Yun-Fei Chen, Cathleen K Clutinger, X. Tigno, B. Hansen, A. Shanafelt, G. Etgen. Endocrinology, 2007

754 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/956ece9cc45ee14b8b240f1a44385df9667954f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response (2009, background): “Pharmacologic administration of FGF21 to insulin-resistant rodents and monkeys improves glucose tolerance and reduces plasma insulin and triglyceride concentrations (15, 17).”
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State (2010, background): “A similar effect has been reported in diabetic monkeys (8).”
Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease (2020, background): “In stark contrast to these effects of physiological FGF21, pharmacological administration of FGF21 in humans and non-human primates reduces blood glucose, insulin, triglycerides, and LDL cholesterol, and increases HDL cholesterol (142, 463, 464).”
Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. (2013, background): “Adiponectin Contributes to the Metabolic Benefits of FGF21 in Both Liver and Skeletal Muscle Since both therapeutic administration and transgenic expression of FGF21 has been shown to improve serum lipid profiles and alleviate fatty liver in mice and nonhuman primates (Xu et al., 2009b; Kharitonenko”
Fibroblast growth factor 21 corrects obesity in mice. (2008, background): “As expected based on previously reported results (2, 4, 5, 7), insulin levels were suppressed, and this effect reached its maximum at the lowest dose of FGF21.”
Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans (2008, background): “More importantly, FGF21 administration led to significant improvements in lipoprotein profiles, including decreased LDL and elevated HDL cholesterol, and beneficial changes in the circulating levels of several cardiovascular factors (16).”
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. (2013, background): “Notably, changes in lipid parameters were very similar to effects we have previously reported after the administration of FGF21 or LY to obese rhesus monkeys with dyslipidemia (Adams et al., 2013a; Kharitonenkov et al., 2007).”
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice (2009, background): “FGF21 has previously been shown to lower blood glucose levels in several diabetic rodent and monkey models (5,8).”
The FGF family: biology, pathophysiology and therapy (2009, positive): “These results are consistent with data from experiments with rhesus monkeys, in which levels of fasting glucose, triglycerides, glucagon and insulin were reduced after FGF21 administratio”
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease (2010, background): “As a pharmacologic agent, administration of FGF21 to obese mice and diabetic monkeys leads to weight loss and marked improvement in glucose and lipid parameters (7, 18, 19).”